QTTB News
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a...
PR Newswire
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a...
PR Newswire
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026 Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the...
PR Newswire
Q32 Bio Appoints Jos Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
Q32 Bio Appoints Jos Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer Q32 Bio Appoints Jos Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development OfficerPR NewswireWALTHAM, Mass., Sept. 14...
PR Newswire
Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Q32 Bio (QTTB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
Q32 Bio to Participate in Upcoming September Investor Conferences
Q32 Bio to Participate in Upcoming September Investor Conferences Q32 Bio to Participate in Upcoming September Investor Conferences PR Newswire WALTHAM, Mass., Sept. 1, 2026 WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company...
PR Newswire
Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 182.2% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Aug. 5, 2026 -- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical...
PR Newswire
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet
The consensus price target hints at an 186% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice
Does Q32 Bio (QTTB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Why Is Q32 Bio Stock Falling Wednesday?
Q32 Bio (QTTB) stock slips after pricing a $200M public offering at $18.25. Get the details on the deal and share reaction.read more...
Benzinga